Plasma alpha-one acid glycoprotein and haloperidol concentrations in schizophrenic patients.
Plasma alpha-one acid glycoprotein and haloperidol concentrations in schizophrenic patients.
复制标题
精神分裂症患者血浆α-1酸性糖蛋白和氟哌啶醇浓度。
DOI：
10.1159/000119357
复制
发表时间：
1997
影响因子：
3.2
通讯作者：
J. Carter
中科院分区：
文献类型：
--
作者：
M. Jann;B. Crabtree;W. M. Pitts;Y. Lam;J. Carter
36例精神分裂症患者随机分为安慰剂组和氟哌啶醇组，治疗6周。在基线和第2、4和6周采集血样，测量血浆α-酸性糖蛋白（AAG）、氟哌啶醇和还原氟哌啶醇浓度。在晚上给药后10-12 h和早晨给药前采集血样。氟哌啶醇和还原氟哌啶醇的测定采用高效液相色谱电化学检测。放射免疫扩散法测定血浆AAG水平。在基线和第2、4和6周，通过简明精神病评定量表（BPRS）和异常不自主运动量表对患者进行临床评估。在安慰剂治疗期间，BPRS评分没有显著降低，尽管发现血浆AAG水平略有下降。氟哌啶醇使BPRS评分和血浆AAG水平显著降低。第6周时平均血浆氟哌啶醇水平为12.9 +/- 14.7 ng/ml。未发现BPRS评分下降与血浆AAG水平之间存在显著相关性，仅在第2周时存在强烈趋势（r = 0.445，p = 0.073）。AAG和精神药物处置在精神病患者中的作用需要进一步评估。
Thirty six schizophrenic patients were randomly assigned to placebo or haloperidol treatment for 6 weeks. Blood samples to measure plasma alpha-one acid glycoprotein (AAG), haloperidol and reduced haloperidol concentrations were obtained at baseline and weeks 2, 4, and 6. Blood samples were obtained 10-12 h after the evening dose and prior to the morning dose. Haloperidol and reduced haloperidol was assayed by HPLC with electrochemical detection. Plasma AAG levels were assayed by radial immunodiffusion. Patients were clinically assessed by the Brief Psychiatric Rating Scale (BPRS) and Abnormal Involuntary Movement Scale at baseline and weeks 2, 4, and 6. BPRS scores did not significantly decrease during placebo treatment, although a slight drop in plasma AAG levels was found. Haloperidol produced a significant decrease in BPRS scores and plasma AAG levels. Mean plasma haloperidol levels were 12.9 +/- 14.7 ng/ml at week 6. Significant correlations between decreasing BPRS scores and plasma AAG levels were not found with only a strong trend at week 2 (r = 0.445, p = 0.073). The role of AAG and psychotropic drug disposition in psychiatric patients requires further evaluation.